Literature DB >> 9177788

Genomic structure and expression of the human heme A:farnesyltransferase (COX10) gene.

T Murakami1, L T Reiter, J R Lupski.   

Abstract

Charcot-Marie-Tooth disease type 1A (CMT1A) is associated with a 1.5-Mb tandem DNA duplication in chromosome 17p11.2-p12, while hereditary neuropathy with liability to pressure palsies (HNPP) is associated with a 1.5-Mb deletion at this locus. The 1.5-Mb CMT1A monomer unit duplicated in CMT1A and deleted in HNPP is flanked by two 24-kb direct repeats termed the CMT1A-REPs. Recently, sequence analysis of the CMT1A-REPs revealed that they contain an internal exon of the COX10 gene. To characterize COX10, encoding human heme A:farnesyltransferase, the genomic region was isolated and the gene structure and expression profile were determined. COX10 spans approximately 135 kb and consists of seven exons. Exons I-V are telomeric to the 1.5-Mb CMT1A monomer unit, whereas exon VII is located within this 1.5-Mb region. Exon VI is contained within the distal CMT1A-REP. All splice sites conform to the GT/AG rule. Analysis of the putative promoter region of the COX10 gene indicates that it lacks conventional TATA and CAAT boxes, but it does have several potential transcription factor-binding sites. This gene is expressed in multiple tissues with highest expression observed in the heart, skeletal muscle, and testis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177788     DOI: 10.1006/geno.1997.4711

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  13 in total

1.  2002 Curt Stern Award Address. Genomic disorders recombination-based disease resulting from genomic architecture.

Authors:  James R Lupski
Journal:  Am J Hum Genet       Date:  2003-02       Impact factor: 11.025

2.  Serial segmental duplications during primate evolution result in complex human genome architecture.

Authors:  Pawełl Stankiewicz; Christine J Shaw; Marjorie Withers; Ken Inoue; James R Lupski
Journal:  Genome Res       Date:  2004-11       Impact factor: 9.043

Review 3.  Charcot-Marie-Tooth disease: lessons in genetic mechanisms.

Authors:  J R Lupski
Journal:  Mol Med       Date:  1998-01       Impact factor: 6.354

4.  Structure and evolution of the Smith-Magenis syndrome repeat gene clusters, SMS-REPs.

Authors:  Sung-Sup Park; Paweł Stankiewicz; Weimin Bi; Christine Shaw; Jessica Lehoczky; Ken Dewar; Bruce Birren; James R Lupski
Journal:  Genome Res       Date:  2002-05       Impact factor: 9.043

5.  Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency.

Authors:  Francisca Diaz; Christine K Thomas; Sofia Garcia; Dayami Hernandez; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2005-08-15       Impact factor: 6.150

6.  Regulation of the heme A biosynthetic pathway: differential regulation of heme A synthase and heme O synthase in Saccharomyces cerevisiae.

Authors:  Zhihong Wang; Yuxin Wang; Eric L Hegg
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

Review 7.  Evolution in health and medicine Sackler colloquium: Genomic disorders: a window into human gene and genome evolution.

Authors:  Claudia M B Carvalho; Feng Zhang; James R Lupski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

Review 8.  Mouse models of oxidative phosphorylation defects: powerful tools to study the pathobiology of mitochondrial diseases.

Authors:  Alessandra Torraco; Francisca Diaz; Uma D Vempati; Carlos T Moraes
Journal:  Biochim Biophys Acta       Date:  2008-06-13

9.  Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease.

Authors:  Massimiliano Vitali; Eliana Venturelli; Daniela Galimberti; Luisa Benerini Gatta; Elio Scarpini; Dario Finazzi
Journal:  J Neural Transm (Vienna)       Date:  2009-10-14       Impact factor: 3.575

10.  Genomic disorders ten years on.

Authors:  James R Lupski
Journal:  Genome Med       Date:  2009-04-24       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.